tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

SRPT Stock Latest News

Sarepta Plunges as FDA Requires More Time for Drug Review
Market NewsSarepta Plunges as FDA Requires More Time for Drug Review
16d ago
CTLT
SRPT
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
23d ago
ATNX
ELOX
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
25d ago
CDTX
HRTX
Sarepta Jumps after FDA Nod for Gene Therapy
Market NewsSarepta Jumps after FDA Nod for Gene Therapy
25d ago
SRPT
Sarepta Therapeutics Halted Ahead of FDA Decision
Market NewsSarepta Therapeutics Halted Ahead of FDA Decision
28d ago
SRPT
Sarepta price target lowered to $158 from $165 at Cantor Fitzgerald
The FlySarepta price target lowered to $158 from $165 at Cantor Fitzgerald
1M ago
SRPT
Sarepta Therapeutics reports Q1 adjusted EPS (97c), consensus ($1.38)
The FlySarepta Therapeutics reports Q1 adjusted EPS (97c), consensus ($1.38)
1M ago
SRPT
SRPT Upcoming Earnings Report: What to Expect?
Pre-EarningsSRPT Upcoming Earnings Report: What to Expect?
1M ago
SRPT
Sarepta initiated with an Outperform at SMBC Nikko
The FlySarepta initiated with an Outperform at SMBC Nikko
1M ago
SRPT
William Blair biotech analyst to hold an analyst/industry conference call
The FlyWilliam Blair biotech analyst to hold an analyst/industry conference call
2M ago
BMRN
KRYS
William Blair biotech analyst to hold an analyst/industry conference call
The FlyWilliam Blair biotech analyst to hold an analyst/industry conference call
2M ago
BMRN
KRYS
William Blair biotech analyst to hold an analyst/industry conference call
The FlyWilliam Blair biotech analyst to hold an analyst/industry conference call
2M ago
BMRN
KRYS
Catalent concerns ‘may be overstated’ for Sarepta, says RBC Capital
The FlyCatalent concerns ‘may be overstated’ for Sarepta, says RBC Capital
2M ago
CTLT
SRPT
Sarepta sees no impact on SRP-9001 from Catalent update, says BofA
The FlySarepta sees no impact on SRP-9001 from Catalent update, says BofA
2M ago
CTLT
SRPT
Morgan Stanley still expects Sarepta to get approval for SRP-9001
The FlyMorgan Stanley still expects Sarepta to get approval for SRP-9001
2M ago
SRPT
Sarepta approval still likely despite STAT article, says William Blair
The FlySarepta approval still likely despite STAT article, says William Blair
2M ago
SRPT
Wave Life selloff on Sarepta article ‘makes no sense,’ says Mizuho
The FlyWave Life selloff on Sarepta article ‘makes no sense,’ says Mizuho
2M ago
WVE
SRPT
Opco says buy Sarepta on selloff, views unchanged after article
The FlyOpco says buy Sarepta on selloff, views unchanged after article
2M ago
SRPT
Sarepta volatility ‘name of the game’ into AdCom and PDUFA date, says Guggenheim
The FlySarepta volatility ‘name of the game’ into AdCom and PDUFA date, says Guggenheim
2M ago
SRPT
Sarepta Drops as Report Hints at Opposition from FDA to its Gene Therapy
Market NewsSarepta Drops as Report Hints at Opposition from FDA to its Gene Therapy
2M ago
SRPT
Baird sees no change to Sarepta AdCom outlook amid ‘drama’ from report
The FlyBaird sees no change to Sarepta AdCom outlook amid ‘drama’ from report
2M ago
SRPT
Sarepta sinks after STAT says FDA leaned against gene therapy approval
The FlySarepta sinks after STAT says FDA leaned against gene therapy approval
2M ago
CTLT
SRPT